Pharming Historical Cash Flow
| PHAR Stock | USD 8.68 0.14 1.64% |
Analysis of Pharming Group cash flow over time is an excellent tool to project Pharming Group NV future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Capital Expenditures of 1.6 M or End Period Cash Flow of 72.2 M as it is a great indicator of Pharming Group ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining Pharming Group NV latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Pharming Group NV is a good buy for the upcoming year.
Pharming |
About Pharming Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in Pharming balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Pharming's non-liquid assets can be easily converted into cash.
Pharming Group Cash Flow Chart
Add Fundamental
Stock Based Compensation
Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.Begin Period Cash Flow
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.Capital Expenditures
Capital Expenditures are funds used by Pharming Group NV to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Pharming Group operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.Most accounts from Pharming Group's cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Pharming Group NV current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pharming Group NV. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. At this time, Pharming Group's Other Cashflows From Investing Activities is relatively stable compared to the past year.
Pharming Group cash flow statement Correlations
Click cells to compare fundamentals
Pharming Group Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Pharming Group cash flow statement Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Change To Inventory | (3.4M) | (5.9M) | (15.0M) | (14.4M) | (13.0M) | (12.3M) | |
| Change In Cash | 123.9M | 2.6M | 15.4M | (145.6M) | (131.0M) | (124.5M) | |
| Free Cash Flow | 74.5M | 20.2M | 20.9M | (18.8M) | (21.6M) | (20.5M) | |
| Change In Working Capital | (3.3M) | (4.7M) | (387K) | (17.0M) | (15.3M) | (14.5M) | |
| Begin Period Cash Flow | 81.5M | 189.2M | 191.9M | 207.3M | 238.4M | 250.4M | |
| Other Cashflows From Financing Activities | (25.5M) | (29.8M) | (4.2M) | 3.6M | 3.2M | 3.1M | |
| Depreciation | 8.9M | 18.7M | 13.2M | 15.9M | 18.3M | 19.2M | |
| Other Non Cash Items | 33.3M | (7.8M) | (11.3M) | (13.5M) | (12.2M) | (11.5M) | |
| Capital Expenditures | 16.5M | 16.0M | 2.0M | 1.5M | 1.7M | 1.6M | |
| Total Cash From Operating Activities | 91.0M | 36.1M | 22.9M | (17.3M) | (19.9M) | (18.9M) | |
| Net Income | 47.5M | 22.0M | 15.0M | (12.0M) | (13.8M) | (13.1M) | |
| Total Cash From Financing Activities | 65.3M | (26.7M) | (5.0M) | (1.0M) | (935.1K) | (888.3K) | |
| End Period Cash Flow | 205.5M | 191.7M | 207.3M | 61.7M | 71.0M | 72.2M | |
| Investments | (288K) | (3.9M) | 5.3M | (129.4M) | (116.4M) | (110.6M) | |
| Net Borrowings | (33.4M) | 73.0M | (2.8M) | (3.3M) | (3.8M) | (3.6M) | |
| Total Cashflows From Investing Activities | (25.2M) | (13.7M) | (18.0M) | 5.3M | 6.1M | 6.4M | |
| Change To Account Receivables | (5.8M) | 5.2M | 2.2M | (16.8M) | (15.1M) | (14.4M) | |
| Change To Operating Activities | (1.1M) | 1.0M | 394K | 273K | 314.0K | 329.6K | |
| Change To Netincome | 25.1M | 36.3M | 6.1M | (3.6M) | (3.2M) | (3.1M) | |
| Change To Liabilities | 7.2M | 2.6M | (4.4M) | 12.0M | 10.8M | 11.3M | |
| Issuance Of Capital Stock | 3.1M | 3.0M | 4.7M | 2.3M | 2.1M | 4.0M | |
| Other Cashflows From Investing Activities | (9.0M) | 0.0 | 6.3M | 21.3M | 24.5M | 25.7M |
Additional Tools for Pharming Stock Analysis
When running Pharming Group's price analysis, check to measure Pharming Group's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pharming Group is operating at the current time. Most of Pharming Group's value examination focuses on studying past and present price action to predict the probability of Pharming Group's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pharming Group's price. Additionally, you may evaluate how the addition of Pharming Group to your portfolios can decrease your overall portfolio volatility.